News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Siena Biotech S.p.A. Chooses Instem’sProvantis to Support In Vivo Activities in Bioanalytical Department
March 21, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Instem, a premier global information solutions provider, announced today that Siena Biotech S.p.A. (“Siena”) has chosen Provantis to structure the flow of their in vivo bioanalytical data in Siena, Italy.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
IPO
2026 IPO stock tracker: How newly public biotechs are performing
July 17, 2026
·
1 min read
·
Gabrielle Masson
Business
GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail
July 17, 2026
·
1 min read
·
Tristan Manalac
Manufacturing
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers
July 16, 2026
·
3 min read
·
John Potter
Psychedelics
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
July 16, 2026
·
2 min read
·
Tristan Manalac